Morgan Stanley set a $100.00 price objective on CVS Health (NYSE:CVS) in a research report sent to investors on Wednesday morning, The Fly reports. The brokerage currently has a buy rating on the pharmacy operator’s stock.

Several other brokerages have also recently issued reports on CVS. Royal Bank of Canada set a $100.00 target price on CVS Health and gave the stock a buy rating in a research report on Wednesday. ValuEngine raised CVS Health from a sell rating to a hold rating in a research report on Thursday, October 11th. Bank of America raised their target price on CVS Health from $86.00 to $90.00 and gave the stock a buy rating in a research report on Monday, September 17th. Wolfe Research began coverage on CVS Health in a research report on Thursday, October 25th. They issued a peer perform rating on the stock. Finally, Tigress Financial reissued a buy rating on shares of CVS Health in a research report on Friday, October 26th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $89.38.

NYSE:CVS traded down $0.22 on Wednesday, hitting $79.83. The stock had a trading volume of 5,761,328 shares, compared to its average volume of 7,892,043. The stock has a market capitalization of $81.55 billion, a price-to-earnings ratio of 13.53, a PEG ratio of 1.07 and a beta of 0.98. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.87 and a current ratio of 2.44. CVS Health has a 52-week low of $60.14 and a 52-week high of $83.88.

CVS Health (NYSE:CVS) last announced its earnings results on Tuesday, November 6th. The pharmacy operator reported $1.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.71 by $0.02. The business had revenue of $47.27 billion for the quarter, compared to analysts’ expectations of $47.22 billion. CVS Health had a return on equity of 18.69% and a net margin of 1.65%. The business’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same period last year, the firm posted $1.50 earnings per share. As a group, equities analysts forecast that CVS Health will post 7.04 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, November 1st. Stockholders of record on Wednesday, October 24th were given a dividend of $0.50 per share. The ex-dividend date was Tuesday, October 23rd. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.51%. CVS Health’s payout ratio is currently 33.90%.

In other news, EVP Eva C. Boratto sold 13,311 shares of CVS Health stock in a transaction dated Monday, September 17th. The stock was sold at an average price of $77.16, for a total transaction of $1,027,076.76. Following the transaction, the executive vice president now directly owns 55,162 shares of the company’s stock, valued at approximately $4,256,299.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Lisa Bisaccia sold 21,534 shares of CVS Health stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $80.00, for a total value of $1,722,720.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 43,409 shares of company stock worth $3,392,097. Insiders own 0.53% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Camarda Financial Advisors LLC purchased a new position in CVS Health in the 2nd quarter worth approximately $102,000. Canton Hathaway LLC purchased a new position in CVS Health in the 3rd quarter worth approximately $126,000. Kiley Juergens Wealth Management LLC purchased a new position in CVS Health in the 2nd quarter worth approximately $103,000. MCF Advisors LLC lifted its holdings in CVS Health by 284.1% in the 3rd quarter. MCF Advisors LLC now owns 1,713 shares of the pharmacy operator’s stock worth $135,000 after purchasing an additional 1,267 shares in the last quarter. Finally, Legacy Advisors LLC lifted its holdings in CVS Health by 7,100.0% in the 2nd quarter. Legacy Advisors LLC now owns 1,800 shares of the pharmacy operator’s stock worth $116,000 after purchasing an additional 1,775 shares in the last quarter. 82.42% of the stock is currently owned by institutional investors.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.

Read More: How to Invest in Growth Stocks

The Fly

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.